WO2019208627A1

WO2019208627A1 - Composition for preventing decrease in muscle mass, preventing decrease in muscular power, increasing muscle mass or enhancing muscular power

Info

Publication number: WO2019208627A1
Application number: PCT/JP2019/017413
Authority: WO
Inventors: 笠島　直樹; 大将吉田; 寿栄鈴木; 優小南; 契吾越前
Original assignee: サントリーホールディングス株式会社
Priority date: 2018-04-27
Filing date: 2019-04-24
Publication date: 2019-10-31
Also published as: JPWO2019208627A1; CN112055544A; JP7227962B2; TW202005556A; TWI821282B

Abstract

The purpose of the present invention is to provide a composition, which comprises as an active ingredient a substance having an effect of preventing a decrease in muscle mass, preventing a decrease in muscular power, increasing muscle mass or enhancing muscular power as well as a high safety and which is to be used for preventing a decrease in muscle mass, preventing a decrease in muscular power, increasing muscle mass or enhancing muscular power, and a method for preventing a decrease in muscle mass, preventing a decrease in muscular power, increasing muscle mass or enhancing muscular power. The composition according to the present invention for preventing a decrease in muscle mass, preventing a decrease in muscular power, increasing muscle mass or enhancing muscular power comprises, as an active ingredient, one or more members of soya sapogenols and/or soya saponins.

Description

Composition for inhibiting muscle mass loss, for inhibiting muscle strength decline, for increasing muscle mass or for increasing muscle strength

The present invention relates to a composition for suppressing muscle mass decrease, for suppressing muscle strength decrease, for increasing muscle mass, or for increasing muscle strength. The present invention also relates to a method for suppressing muscle mass decrease, suppressing muscle strength decrease, increasing muscle mass, or increasing muscle strength. The present invention also relates to the use of one or more soyasapogenols and / or soyasaponins for inhibiting muscle mass reduction, inhibiting muscle strength reduction, increasing muscle mass or increasing muscle strength.

In countries such as Japan with a high proportion of elderly people, extension of healthy life expectancy and improvement of quality of daily life (QOL) are challenges. One of the factors for shortening the healthy life expectancy is a decrease in muscle mass (muscle mass) and a decrease in muscle strength with aging. A decrease in muscle mass and strength leads to an increased risk of falls, injuries such as fractures, and long-term bed rest. When the amount of activity of the elderly decreases due to injury, illness, etc., a vicious circle in which the muscle mass and strength are further reduced is caused, causing locomotive syndrome and the like.

In addition, muscle mass and strength also decrease when there is a lack of exercise due to development of transportation means, or when a long-term rest is required for treatment of illness after surgery, etc. In order to return to daily life sooner after healing, it is desirable to suppress a decrease in muscle mass and a decrease in muscle strength.

Exercise therapy such as rehabilitation is performed as one means for suppressing or increasing the decrease in muscle mass or strength. On the other hand, research has been conducted on ingredients having a muscle strengthening action from a nutritional viewpoint. For example, Patent Document 1 describes that when maslinic acid and oleanolic acid were ingested, skeletal muscle mass increased and resistance to grip increased after resistance training without using a training device, compared to the case of ingestion. .

JP 2017-109942 A

Exercise therapy is difficult to carry out continuously due to time and physical reasons, and it may be physically burdensome for the elderly. Therefore, there is a demand for the development of a substance that is highly safe and effective for suppressing the decrease in muscle mass, suppressing the decrease in muscle strength, increasing the muscle mass, or increasing the muscle strength by ingestion or the like. Although maslinic acid and oleanolic acid described in Patent Document 1 are components contained in plants such as olives and are considered to be highly safe, they are substances having more excellent muscle mass reduction inhibitory activity, muscle strength reduction inhibitory effect, etc. Development is desired.

The present invention has a muscle mass reduction inhibitory effect, a muscle strength reduction inhibitory effect, a muscle mass increase effect or a muscle strength increase effect, and contains a highly safe substance as an active ingredient for muscle mass reduction inhibition, for muscle strength reduction inhibition An object of the present invention is to provide a composition for increasing muscle mass or increasing muscle strength. Another object of the present invention is to provide a method for suppressing a decrease in muscle mass, suppressing a decrease in muscle strength, increasing a muscle mass, or increasing a muscle strength.

As a result of diligent research in view of the above problems, the present inventors have found that soyasapogenols and soyasaponins, which are glycosides thereof, have excellent muscle mass reduction inhibitory activity, muscle strength reduction inhibitory effect, muscle mass increasing effect, or muscle strength increasing effect. Based on this finding, the present invention has been completed.

That is, although not limited thereto, the present invention relates to the following composition, method and use for suppressing muscle mass decrease, for suppressing muscle strength decrease, for increasing muscle mass or for increasing muscle strength.
[1] A composition for suppressing muscle mass decrease, for suppressing muscle strength decrease, for increasing muscle mass or for increasing muscle strength, comprising at least one of soyasapogenols and / or soyasaponins as an active ingredient.
[2] The composition according to the above [1], comprising at least one of the soyasapogenols as an active ingredient.
[3] The composition according to [1] or [2] above, wherein at least one of the soyasapogenols is soyasapogenol A and / or soyasapogenol B.
[4] The composition according to [1] above, which contains one or more soyasaponins as an active ingredient.
[5] The composition according to [1] or [4] above, wherein at least one soyasaponins is one or more of group A soyasaponins and / or group B soyasaponins.
[6] “Muscle loss suppression”, “Muscle maintenance”, “Muscle increase”, “Muscle improvement”, “Muscle strength reduction suppression”, “Muscle strength maintenance”, “Muscle strength increase”, “Muscle strength improvement”, “Muscle building power” Support "," Improvement of walking function "," Maintenance of walking function "," Improvement of motor function "," Maintenance of motor function "," Maintenance of muscle that weakens with aging "and" Maintenance of muscle strength that weakens with aging " The composition according to any one of the above [1] to [5], which is marked with 1 or 2 or more.

[7] A method for suppressing muscle mass reduction, suppressing muscle strength reduction, increasing muscle mass or increasing muscle strength, comprising administering one or more soyasapogenols and / or soyasaponins.
[8] Use of one or more kinds of soyasapogenols and / or soyasaponins for suppressing muscle mass reduction, muscle strength reduction, muscle mass increase or muscle strength increase.
[9] The method described in [7] above, wherein one or more soyasapogenols are administered.
[10] The method according to [7] or [9] above, wherein at least one soyasapogenol is soyasapogenol A and / or soyasapogenol B.
[11] The method described in [7] above, wherein one or more soyasaponins are administered.
[12] The method according to [7] or [11] above, wherein at least one soyasaponins is one or more of group A soyasaponins and / or group B soyasaponins.
[13] The use according to [8] above, which is one or more kinds of soyasapogenols.
[14] The use according to [8] or [13] above, wherein at least one of the soyasapogenols is soyasapogenol A and / or soyasapogenol B.
[15] The use according to the above [8], which is one or more types of soyasaponins.
[16] The use according to [8] or [15] above, wherein at least one soyasaponin is at least one of group A soyasaponins and / or group B soyasaponins.

ADVANTAGE OF THE INVENTION According to this invention, it has a muscle mass reduction inhibitory effect, a muscular strength reduction inhibitory effect, a muscular mass increase effect, or a muscular strength increase effect, and contains a highly safe substance as an active ingredient, for muscular mass reduction suppression, muscular strength reduction Compositions for suppression, muscle mass increase or muscle strength increase are provided. In addition, according to the present invention, there is provided a method for suppressing a decrease in muscle mass, suppressing a decrease in muscle strength, increasing a muscle mass, or increasing a muscle strength. According to the present invention, for example, a decrease in muscle mass or a decrease in muscle strength due to factors such as aging can be suppressed, or a muscle mass or muscle strength can be increased to maintain the muscle mass or muscle strength. For this reason, this invention can provide the new means which contributes to improvement of QOL, such as elderly people. Soyasapogenols and soyasaponins used in the present invention for suppressing muscle mass decrease, muscle strength decrease, muscle mass increase or muscle strength increase are components that are also included in soybeans and other food plants, and continue to be highly safe. It is also advantageous in that it can be ingested.

FIG. 1 is a graph showing the results of examining changes in muscle strength with age for C57BL / 6J male mice. FIG. 2 is a graph showing the grip strength change rate (grip strength at the end of the test / grip strength at the start of the test) of each of the control group, the soyasaponin group, and the soyasapogenol group. FIG. 3 is a graph showing the ratio of both hindlimb muscle weights per body weight of the control group, soyasaponin group, and soyasapogenol group (both hindlimb muscle weight / body weight). FIG. 4 is a graph showing the amount of protein synthesis in the gastrocnemius muscle of mice administered with the soyasapogenol crude fraction. FIG. 5 is a graph showing the amount of phosphorylated p70S6K (T389) in gastrocnemius muscle of mice administered with the crude fraction of soyasapogenol. FIG. 6 is a graph showing the amount of protein synthesis in the gastrocnemius muscle of mice administered with soyasapogenol A, soyasapogenol B, maslinic acid or oleanolic acid. FIG. 7 is a graph showing the results of examining the myotube differentiation promoting effect of the soyasapogenol crude fraction using normal human skeletal myoblasts.

The composition for inhibiting muscle mass reduction, inhibiting muscle strength reduction, increasing muscle mass or increasing muscle strength of the present invention contains at least one soyasapogenol and / or soyasaponins as an active ingredient.
The composition of the present invention can also be expressed as a composition for suppressing muscle mass decrease, a composition for suppressing muscle strength decrease, a composition for increasing muscle mass, or a composition for increasing muscle strength. An increase in muscle mass or strength can also be referred to as muscle augmentation. The composition for suppressing muscle mass decrease, for suppressing muscle strength decrease, for increasing muscle mass, or for increasing muscle strength of the present invention is hereinafter also simply referred to as the composition of the present invention.

Soyasapogenols (also referred to as soyasapogenol compounds) and soyasaponins (also referred to as soyasaponin compounds) are compounds contained in legumes such as soybean (scientific name: Glycine max). In the composition of the present invention, only one kind of compound may be used as one or more kinds of soyasapogenols and / or soyasaponins, or two or more kinds of compounds may be used.

Examples of soyasapogenol compounds in the present invention include soyasapogenol A and soyasapogenol B. The soyasapogenols in the present invention include one or more of these compounds. In one embodiment, the composition of the present invention preferably contains at least one soyasapogenol as an active ingredient. Soyasapogenol A and / or soyasapogenol B is preferred as one or more of the soyasapogenols from the viewpoint of a muscle mass decrease inhibiting effect, a muscle strength decline inhibiting effect, a muscle mass increasing effect or a muscle strength increasing effect.

The soyasaponins are glycosides having the above-mentioned soyasapogenols as aglycones. Examples of the soyasaponins compounds include group A soyasaponins, group B soyasaponins and the like. Group A soyasaponins are glycosides having soyasapogenol A as an aglycon. Group B soyasaponins are glycosides having soyasapogenol B as an aglycon. Soyasapogenols contain one or more compounds. The composition of the present invention may contain at least one soyasaponin as an active ingredient. From the viewpoint of the muscle mass decrease inhibitory effect, muscle strength decrease inhibitory effect, muscle mass increasing effect or muscle strength increasing effect, one or more of the group A soyasaponins and / or the group B soyasaponins are preferred as one or more of the soyasaponins.

Examples of Group A Soyasaponins include Soyasaponin Aa (Soyasaponin A4), Soyasaponin Ab (Soyasaponin A1), Soyasaponin Ac, Soyasaponin Ad, Soyasaponin Ae (Soyasaponin A5), Soyasaponin A2 (Soyasaponin A2) Ah (Soyasaponin A3) is mentioned. Of these, Soyasaponin Aa and Soyasaponin Ab are preferable.

Examples of group B soyasaponins include soyasaponin Ba (soyasaponin V), soyasaponin Bb (soyasaponin I), soyasaponin Bc (soyasaponin II), soyasaponin Bb '(soyasaponin III), and soyasaponin Bc' (soyasaponin IV). Of these, Soyasaponin Ba and Soyasaponin Bb are preferable.

In one embodiment, soyasapogenols and / or soyasaponins are preferably soyasapogenols, and more preferably soyasapogenol A and / or soyasapogenol B.

There are no particular restrictions on the origin and production method for obtaining soyasapogenols and / or soyasaponins. Soybeans (especially soybean seeds (soybeans)), red beans, kudzu roots, and the like are known as plants or their parts rich in soyasapogenols and / or soyasaponins. From these plants, soyasapogenols and / or soyasaponins can be extracted and purified by a known method. Soyasapogenols can also be obtained by hydrolyzing soyasaponins by a known method. Commercially available products can be used as the soyasapogenols and soyasaponins.

In the present invention, as long as the effects of the present invention are exhibited, a plant-derived raw material containing one or more kinds of soyasapogenols and / or soyasaponins may be contained in the composition of the present invention. Examples of plant-derived materials rich in one or more of soyasapogenols and / or soyasaponins include, for example, soybean seeds that are raw or dried by freeze-drying, and soy seeds extracted with hot water or an organic solvent A solution (extract) obtained by concentrating or freeze-drying, or a product obtained by purifying a dried extract solution with a column or the like and purifying soyasapogenols and / or soyasaponins can be used. As the plant-derived raw material containing at least one kind of soyasapogenols and / or soyasaponins, a commercially available one may be used, or it may be prepared from a plant such as soybean by a known method.

As shown in Examples, when soy sapogenols or soy saponins were fed to an old mouse, the grip strength of the mouse increased. In addition, the intake of soyasapogenols or soyasaponins increased the proportion of muscle weight per body weight of old mice. Moreover, when protein synthesis amount decreased by fasting, the amount of muscle protein synthesis significantly increased in mice fed with soyasapogenols compared to the fasted group. In mice fed with soyasapogenols, phosphorylation of p70S6 kinase (p70S6K) was also promoted. p70S6K is a major factor controlling muscle protein synthesis, and when phosphorylated, muscle protein synthesis is promoted. Therefore, promotion of phosphorylation of p70S6K promotes muscle protein synthesis, resulting in suppression or increase in muscle mass. By suppressing or increasing the decrease in muscle mass by promoting the synthesis of muscle protein, an effect of suppressing or increasing muscle strength can be obtained.
Moreover, the amount of muscle protein synthesis was higher in mice fed with one or more of the soyasapogenols than in mice fed with oleanolic acid and maslinic acid. This means that soyasapogenols exhibit a muscle mass decrease inhibitory effect, muscle strength reduction inhibitory effect, muscle mass increasing effect or muscle strength increasing effect superior to oleanolic acid and maslinic acid. Furthermore, as shown in the Examples, the fraction containing soyasapogenols promoted differentiation from myoblasts to myotubes. Muscles are formed from muscle fibers in which myoblasts are differentiated into myotube cells and myotube cells are fused. The promotion of differentiation from myoblasts to myotubes results in the suppression or increase in muscle mass and the suppression or increase in muscle strength. As for soyasaponins, ingested soyasaponins become soyasapogenols in the body due to the action of digestive enzymes or metabolic enzymes, and are considered to exhibit the same effects as soyasapogenols in the body.
Therefore, soyasapogenols and / or soyasaponins have a muscle mass decrease inhibitory effect, a muscle strength decrease inhibitory effect, a muscle mass increase effect or a muscle strength increase effect, and to suppress muscle mass decrease, Can be used to increase muscle strength or muscle strength. Soyasapogenols and / or soyasaponins can also be used to promote differentiation of myoblasts into myotubes in order to promote phosphorylation of p70S6 kinase.

The composition of the present invention exhibits an excellent muscle mass reduction inhibitory effect, muscle strength reduction inhibitory effect, muscle mass increase effect, or muscle strength increase effect by including one or more soyasapogenols and / or soyasaponins as active ingredients. In addition, such effects can prevent, for example, the reduction of muscle mass, the maintenance of muscle mass, the prevention of muscle weakness, the maintenance of muscle strength, the improvement of a state in which the muscle mass is reduced or the muscle strength is reduced, and the like. Therefore, the composition of the present invention can prevent muscle loss, prevent muscle weakness, improve the state of reduced muscle mass, improve the state of reduced muscle strength, maintain muscle mass, Can be used for maintenance etc. In one aspect, the composition of the present invention is suitably used for suppressing the decrease in muscle mass or suppressing the decrease in muscle strength, for example, for suppressing the decrease in muscle mass due to muscle atrophy due to aging, for suppressing the decrease in muscle strength, etc. It can be suitably used. As the muscle, skeletal muscle is preferable, and muscles such as legs are exemplified. The increase in muscle mass can be an increase in muscle weight per body weight.
The muscle mass of animals such as humans can be measured by, for example, microPET / CT (positron emission tomography / computed tomography, INVEON, Siemens, USA).

The composition of the present invention can be used for treatment of a condition or disease for which prevention or improvement can be expected by suppressing muscle mass decrease, suppressing muscle strength decrease, increasing muscle mass, or increasing muscle strength. Examples of such conditions or diseases include locomotive syndrome, cachexia (caused by debilitating diseases such as cancer and chronic diseases, severe skeletal muscle atrophy and organ dysfunction due to loss of appetite and metabolic regulation mechanisms. Examples include a state or disease in which muscle mass is reduced or muscle strength is reduced, such as a state showing a disease state.
As used herein, prevention of a condition or disease refers to preventing the onset of the condition or disease, delaying the onset of the condition or disease, reducing the incidence of the condition or disease, and risk of developing the condition or disease. Includes mitigation. Improvement of a condition or disease includes restoring the subject from the condition or disease, reducing the symptoms of the condition or disease, delaying or preventing the progression of the condition or disease.

The composition of the present invention can be applied to either a therapeutic use (medical use) or a non-therapeutic use (non-medical use).
Although the composition of this invention can be provided with forms, such as food / beverage products, a pharmaceutical, a quasi-drug, and a feed, for example, it is not limited to these. The composition of the present invention may itself be a food / beverage product, a pharmaceutical product, a quasi-drug, a feed or the like, or may be a preparation or a material such as an additive used in these. Although the composition of this invention can be provided with the form of an agent as an example, it is not limited to this form. The agent can be provided as it is as a composition or as a composition containing the agent. The composition of the present invention can also be referred to as an agent for inhibiting muscle mass reduction, inhibiting muscle strength reduction, increasing muscle mass, or increasing muscle strength.
In one embodiment, the composition of the present invention is preferably an oral composition. ADVANTAGE OF THE INVENTION According to this invention, the composition for oral administration which has the outstanding muscle mass reduction | decrease suppression, muscular strength fall suppression, a muscular volume increase, or a muscular strength increase effect can be provided. Examples of the oral composition include foods and drinks, pharmaceuticals, and quasi drugs, preferably foods and drinks.

Unless the effect of this invention is impaired, the composition of this invention can contain arbitrary additives and arbitrary components other than the above-mentioned Soyasapogenols and / or Soyasaponins. These additives and components can be selected according to the form of the composition and the like, and generally usable for foods and drinks, pharmaceuticals, quasi drugs, feeds and the like.

When the composition of the present invention is used as a food or drink, one or more soyasapogenols and / or soyasaponins can be used in the food or drink (for example, food and drink materials, additives used as necessary). Can be made into various foods and drinks. Food / beverage products are not specifically limited, For example, general food / beverage products, health food, food additives, these raw materials, etc. are mentioned. The form of the food or drink is not particularly limited, and examples thereof include a solid form, a semi-fluid form, and a fluid form. Foods and beverages include tablets, coated tablets, fine granules, granules, powders, pills, capsules, dry syrups, chewables and other oral solid preparations; oral liquid preparations, syrups and other oral liquid preparations It can also be.

When the composition of the present invention is used as a pharmaceutical product or quasi-drug, one or more of soyasapogenols and / or soyasaponins are blended with pharmacologically acceptable excipients, etc. It can be. From the viewpoint of obtaining the effects of the present invention more sufficiently, the administration form of a pharmaceutical product or quasi drug is preferably oral administration. The dosage form may be a dosage form suitable for the dosage form. Oral pharmaceutical dosage forms, for example, oral solid preparations such as tablets, coated tablets, fine granules, granules, powders, pills, capsules, dry syrups, chewables; oral preparations such as oral liquids and syrups Liquid formulations are mentioned. The medicament may be a non-human animal medicament.

When the composition of the present invention is used as a feed, a feed that can be used in the feed can be blended with one or more of the soyasapogenols and / or soyasaponins. Examples of the feed include livestock feed used for cattle, pigs, chickens, sheep, horses, etc .; feed for small animals used for rabbits, guinea pigs, rats, mice, etc .; pet food used for dogs, cats, birds, etc. .

When the composition of the present invention is used as a food / beverage product, pharmaceutical product, quasi-drug, feed, etc., its production method is not particularly limited, and at least one of soyasapogenols and / or soyasaponins used as an active ingredient is used. And can be produced by a general method.
In the production of the composition of the present invention, a purified compound may be used as soyasapogenols and / or soyasaponins, and a plant-derived material rich in one or more of the above-mentioned soyasapogenols and / or soyasaponins May be used. Soyasapogenols and / or soyasaponins may be contained in the composition in the form of a plant-derived raw material containing the compound.

In the composition of the present invention, one or more of the use, the type of active ingredient, the effects described above, the usage method (for example, the ingestion method, the administration method), etc. may be displayed on a package, container or instruction. . The composition of the present invention may have an indication that it has a muscle mass decrease inhibitory effect, a muscle strength decline inhibitory effect, a muscle mass increase effect or a muscle strength increase effect, or an action based on these effects. The composition of the present invention includes, for example, “inhibition of muscle loss”, “muscle maintenance”, “muscle increase”, “muscle improvement”, “muscle strength reduction inhibition”, “muscle strength maintenance”, “muscle strength increase”, “muscle strength improvement” ”,“ Support muscle building power ”,“ Improvement of walking function ”,“ Maintenance of walking function ”,“ Improvement of motor function ”,“ Maintenance of motor function ”,“ Maintenance of muscles that decline with aging ”and“ Aging ” One or two or more indications such as “maintenance of muscular strength that weakens by” may be attached.

The content of soyasapogenols and / or soyasaponins in the composition of the present invention can be appropriately set according to the form of the composition. For example, the total content of soyasapogenols and soyasaponins may be 0.01-90% by weight in the composition. In one embodiment, when the composition of the present invention is an oral composition such as foods and drinks, pharmaceuticals, and quasi drugs, the total content of soyasapogenols and soyasaponins is 0.01% by weight in the composition. The above is preferable, 0.2% by weight or more is more preferable, 20% by weight or less is preferable, and 10% by weight or less is more preferable. In one embodiment, the total content of soyasapogenols and soyasaponins is preferably 0.01 to 20% by weight, more preferably 0.2 to 10% by weight in the composition of the present invention. The total content is the total amount of soyasapogenols and / or soyasaponins when two or more compounds are contained. The content of soyasapogenols and / or soyasaponins can be measured according to a known method, for example, HPLC method or the like can be used.

The composition of the present invention can be ingested or administered by an appropriate method according to its form. The composition of the present invention is preferably administered orally or ingested.
The amount of intake (also referred to as a dose) of the composition of the present invention is not particularly limited, and is an amount (effective amount) that provides a muscle mass decrease inhibitory effect, muscle strength decrease inhibitory effect, muscle mass increase effect, or muscle strength increase effect. ) And may be set as appropriate according to the dosage form, administration method, and the like. For example, when orally administered to humans (adults) or ingested, the total intake of soyasapogenols and soyasaponins is preferably 5 mg or more, more preferably 10 mg or more, still more preferably 20 mg or more, Moreover, 500 mg or less is preferable, 200 mg or less is more preferable, and 100 mg or less is further more preferable. As one aspect, when a human (adult) is orally administered or ingested to a subject, the intake of the composition of the present invention is preferably 5 to 500 mg per day as the total intake of soyasapogenols and soyasaponins. 10 to 200 mg is more preferable, and 20 to 100 mg is more preferable. The above amount is preferably administered or taken orally once a day or divided into 2 to 3 times a day. In the case of ingesting the composition of the present invention for the purpose of obtaining the effect of suppressing muscle mass decrease, the effect of suppressing muscle strength decrease, the effect of increasing muscle mass or the effect of increasing muscle strength in humans (adults), the total of soyasapogenols and soyasaponins It is preferred that the composition of the present invention be orally ingested or administered to a subject so that the intake amount falls within the above range.

In one embodiment, the composition of the present invention takes into consideration the dosage form, administration method, and the like, in an amount that provides the desired effect of the present invention, that is, an effective amount of the above-mentioned soyasapogenols and / or soyasaponins. It is preferable to contain seeds or more. As one aspect, for example, when the composition of the present invention is an oral composition such as foods and drinks and oral pharmaceuticals, the total content of soyasapogenols and soyasaponins in the daily intake per adult of the composition The amount is preferably 5 to 500 mg, more preferably 10 to 200 mg, and even more preferably 20 to 100 mg.

It is expected that soyasapogenols and / or soyasaponins are continuously ingested (administered) to increase the muscle mass reduction suppression, muscle strength reduction suppression, muscle mass increase, or muscle strength increase effect. In a preferred embodiment, the composition of the present invention is to be taken continuously. In one embodiment of the present invention, the composition of the present invention is preferably taken continuously for 1 week or longer, more preferably 4 weeks or longer, and even more preferably 8 weeks or longer.

The subject to be administered or ingested the composition of the present invention (hereinafter, also simply referred to as “administration subject”) is preferably a mammal (human and non-human mammal), more preferably a human. Moreover, as a subject to be administered in the present invention, a subject requiring or desiring to suppress muscle mass decrease, muscle strength decrease, muscle mass increase or muscle strength increase is preferable. For example, a subject whose muscle mass has decreased, a subject whose muscle strength has declined, a subject whose muscle mass has been reduced or whose muscle strength has been reduced, or a subject who wishes to prevent or ameliorate a disease, etc. can be mentioned as suitable subjects. In one aspect, the subject of administration of the composition of the present invention is preferably elderly. Soyasapogenols and / or soyasaponins are suitably used, for example, for the suppression of muscle mass loss (reduction in muscle mass due to aging) and the suppression of muscle strength reduction (reduction in muscle strength due to aging) in the elderly. In one embodiment, the composition of the present invention is used for a subject in a healthy state for the purpose of preventing a decrease in muscle mass, suppressing a decrease in muscle strength, a state in which improvement can be expected by an increase in muscle mass or an increase in muscle strength, or a disease. be able to.

The present invention also includes the following methods for suppressing muscle mass decrease, suppressing muscle strength decrease, increasing muscle mass, or increasing muscle strength.
A method for suppressing muscle mass decrease, suppressing muscle weakness, increasing muscle mass or increasing muscle strength, comprising administering one or more of soyasapogenols and / or soyasaponins.
The method may be a therapeutic method or a non-therapeutic method. “Non-therapeutic” is a concept that does not include medical practice, ie surgery, treatment or diagnosis.
The dose of soyasapogenols and / or soyasaponins is not particularly limited as long as it is an amount that can provide a muscle mass decrease inhibitory effect, muscle strength decrease inhibitory effect, muscle mass increase effect, or muscle strength increase effect, that is, an effective amount. It is preferred to administer the amounts described above. Soyasapogenols and / or soyasaponins may be administered as they are, or may be administered as a composition containing one or more of soyasapogenols and / or soyasaponins. For example, the composition of the present invention described above can be administered. Soyasapogenols and / or soyasaponins, administration subjects, administration methods, dosages and preferred embodiments thereof are the same as those in the composition of the present invention described above. ADVANTAGE OF THE INVENTION According to this invention, the side effect is not produced, but the outstanding muscle mass reduction | decrease suppression, muscular strength fall suppression, muscle mass increase, or a muscular strength increase effect can be acquired safely.

The present invention also encompasses the use of one or more soyasapogenols and / or soyasaponins for inhibiting muscle mass loss, inhibiting muscle weakness, increasing muscle mass or increasing muscle strength.
The above use is usually used in a human or non-human animal, preferably a human or non-human mammal, more preferably a human. The use may be therapeutic or non-therapeutic. Preferred embodiments such as soyasapogenols and / or soyasaponins are the same as those of the composition of the present invention described above.

In the method and use of the present invention, one or more kinds of soyasapogenols and / or soyasaponins may be used, or two or more compounds may be used. In the above method and use, it is preferable to continuously administer one or more soyasapogenols and / or soyasaponins. In one aspect, it is preferable to administer one or more soyasapogenols and / or soyasaponins, preferably continuously for 1 week or more, more preferably 4 weeks or more, and even more preferably 8 weeks or more.

In one aspect, the present invention also includes the use of one or more soyasapogenols and / or soyasaponins for producing a composition for inhibiting muscle mass loss, for inhibiting muscle weakness, for increasing muscle mass, or for increasing muscle strength. To do. Soyasapogenols and / or soyasaponins, muscle mass reduction suppression, muscle strength reduction suppression, muscle mass increase or muscle strength increase composition and preferred embodiments thereof are the same as the above-described composition of the present invention and preferred embodiments thereof It is.

EXAMPLES Hereinafter, although an Example demonstrates this invention further in detail, this does not limit the scope of the present invention.

All animal experiments including examples and comparative examples were conducted in accordance with the plan approved by the head of the institution after reviewing the in-house animal experimentation committee in compliance with the Animal Protection Law and other related laws and regulations.

<Preparation Example 1>
Method for obtaining soyasaponin and method for preparing soyasapogenol crude fraction In the following test, as soyasaponin, a commercially available soybean-derived saponin (saponin B-50 manufactured by J-Oil Mills Co., Ltd. (group B soybean saponin content is 60% by weight, A The group soybean saponin content was evaluated using 13 wt%)). Group B soybean saponins in saponin B-50 include soya saponin Ba and soya saponin Bb, and group A soybean saponins include soya saponin Aa and soya saponin Ab.
A fraction containing soybean-derived sapogenol was prepared by the following method. Saponin B-50 was reacted in a 20-fold amount of 2N aqueous hydrochloric acid at 100 ° C. for 2 hours to cleave the saponin sugar chain. After completion of the reaction, the reaction solution was cooled to room temperature and neutralized with an aqueous sodium hydroxide solution. The reaction solution was subjected to suction filtration, the residue was washed with a large amount of distilled water, and suction filtration was repeated. After confirming that no sodium hydroxide remained, the residue was dried and soyasapogenol crude fraction (purity 50%: soyasapogenol A and B). Total).

<Test Example 1>
Decrease in muscle strength due to aging of C57BL / 6J male mice In order to confirm the age-related changes in muscle strength of C57BL / 6J male mice (Nippon Charles River Co., Ltd.), the transition of the total limb grip strength as an index was examined. The total grip strength of the limbs at 7 months of age (23 animals), 20 months of age (22 animals), 22 months of age (7 animals) and 24 months of age (7 animals) was measured using the grip strength measuring device (MK-380S, Muromachi Machine Co., Ltd.) Company) and measured the grip strength. Dunnett's multiple comparison test was used for the significant difference test. The grip strength measurement results of each group of 7 months old (7M), 20 months old (20M), 22 months old (22M) and 24 months old (24M) are shown in FIG. 1 (*: P <0.05, ** : P <0.01, compared with 7 months old). The results are shown as the mean value ± standard error of each group. As a result of statistical analysis, it can be seen that the grip strength of 20-month-old, 22-month-old, and 24-month-old mice is significantly lower than that of 7-month-old mice. From this result, it was confirmed that a decrease in muscle strength accompanying aging can be observed in mice of the above strain.

<Example 1>
Soya saponin and soya sapogenol crude fraction decrease suppression or increase action and muscular strength decrease suppression or increase action Soya saponin and soya sapogenol crude fraction show muscular strength decrease suppression or increase effect on aging muscle weakness? It was evaluated by measuring the grip strength of the limbs of mice. At the same time, it was also examined whether or not there was an effect of suppressing or increasing the hind limb muscle weight. As the soyasapogenol crude fraction, the one prepared in Preparation Example 1 was used.

(Test method)
70-week-old C57BL / 6J male mice (Nippon Charles River Co., Ltd.) were preliminarily raised for 8 weeks. Mice after pre-breeding (old mice) were divided into three groups: a control group, a soyasaponin group, and a soyasapogenol group. Each group was evaluated with 5 to 8 animals.
In the control group, CE-2 feed (CLEA Japan, Inc.) was allowed to eat freely for 8 weeks (test period). The soyasaponin group contains CE-2 feed containing 0.5% by weight of saponin B-50 (manufactured by J-Oil Mills Co., Ltd.), and the soyasapogenol group contains 0.5% by weight of the crude soyasapogenol fraction. The formulated CE-2 feed was fed ad libitum for 8 weeks.
After the test period, the mouse body weight, hind limb muscle weight and grip strength were measured. The grip strength was measured by using a grip strength measuring device (MK-380S, Muromachi Kikai Co., Ltd.) as the total grip strength of the mouse limbs. At the end of the test, the muscle weights of the hind limbs were collected from the gastrocnemius, soleus, plantar muscles, anterior tibial muscles, extensor extensors and quadriceps muscles, and weighed. As an evaluation index of muscle weight, the ratio of both hind limb muscle weights per body weight (total weight of gastrocnemius, soleus, plantar, anterior tibial, long extensor and quadriceps) was determined. Dunnett's multiple comparison test was used for the significant difference test. Significance level P <0.05 was considered significant.

(result)
1-1 Grip strength measurement results For each group, the grip strength change rate (grip strength at the end of the test / grip strength at the start of the test) obtained by dividing the grip strength at the end of the test by the grip strength at the start of the test was determined. The rate of change in grip strength of each of the control group, soyasaponin group and soyasapogenol group is shown in FIG. 2 (**: P <0.01, compared with the control group). The results shown in FIG. 2 are shown as the mean value ± standard error of each group. As a result of statistical analysis, a significant increase in grip strength was confirmed in the Soyasaponin group compared with the control group, and an increase in grip strength was also confirmed in the Soyasapogenol group.

1-2 Muscle Weight Measurement Results For each group, the ratio of both hind limb muscle weights per body weight (both hind limb muscle weights / body weight) obtained by dividing both hind limb muscle weights at the end of the test by body weight was determined. FIG. 3 shows the ratio of both hind limb muscle weights per body weight of the control group, soyasaponin group, and soyasapogenol group. The results shown in FIG. 3 are shown as the mean value ± standard error of each group. As a result of statistical analysis, an increase in the ratio of the weight of both hindlimb muscles per body weight was confirmed in the soyasaponin group and the soyasapogenol group as compared to the control group.

From the above, it was confirmed that soyasaponins and soyasapogenols have an effect of maintaining muscle strength by suppressing or increasing muscle strength associated with aging. Moreover, the effect of increasing the proportion of hindlimb muscle weight per body weight was confirmed for soyasaponins and soyasapogenols.

<Example 2>
Evaluation of muscle protein synthesis and muscle synthesis signal (soyasapogenol crude fraction)
(Test method)
(reagent)
Ponceau S solution was purchased from Sigma-Aldrich. Sodium carboxymethylcellulose (CMC-Na), Extra PAGE One Precast Gel, and Blocking one were purchased from Nacalai Tesque. The Tissue Protein Extraction Reagent, the Protease Inhibitor Cocktail Kit, and the Pierce BCA protein assay kit were purchased from Thermo Fisher Scientific. Puromycin was purchased from InvivoGen, and Anti-puromycin was purchased from Millipore. Anti-β-actin, Anti-mouse IgG, HRP-linked Antibody, Anti-rabbit IgG, HRP-linked Antibody, Phospho-p70 S6 Kinase (Thr389) Sandwich ELIS from TG PVDF membranes were purchased from Invitrogen and ECL Western Blotting Detection Reagents from General Electric Company. As the soyasapogenol crude fraction, the one prepared in Preparation Example 1 was used.

(animal)
Male 7-week-old C57BL6J mice were purchased from Clea Japan, Inc. and subjected to experiments after a 1-week acclimatization period. The animals were raised in a breeding room with air conditioning (temperature 23.5 ± 1.0 ° C., humidity 55 ± 10%, ventilation rate 12-15 times / hour, lighting 7: 00-19: 00 / day). During the acclimation period, commercial feed (CE-2, Nippon Claire Co., Ltd.) and tap water were freely consumed.

After the habituation period, 30 mice were divided into the following 3 groups.
Saturation group (Cont.) N = 6
Fasting group (Fast.) N = 12
Fasting + Soyasapogenol crude fraction group (Fast. + SS) n = 12
Fasting for 24 hours was performed on the two groups excluding the satiety group. After the fasting, immediately after fasting, 7 hours after fasting, and 22 hours after fasting, it was divided into three times: 0.5% CMC-Na aqueous solution for the fasting group and fasting group, and the fasting + soyasapogenol crude fraction group 26 mg / kg (26 mg / kg body weight per time) of the soyasapogenol crude fraction suspended in 0.5% CMC-Na aqueous solution was orally administered (the dose of the crude soyasapogenol fraction was 78 mg / kg body weight). Twenty-three hours after fasting, 1.25 mM puromycin aqueous solution was intraperitoneally administered at 200 μL / head to all groups. Individuals whose solution leaked from the abdominal cavity when puromycin was administered, or individuals whose intraperitoneal hemorrhage was confirmed during laparotomy under anesthesia were considered to have an effect on the uptake of puromycin into the tissue, and were excluded from the analysis at this stage did. After the test was completed 24 hours after fasting, gastrocnemius muscle was collected and stored frozen at -80 ° C.

For the collected gastrocnemius muscle, the amount of protein synthesis was measured by the following method. The amount of p70S6K (phosphorylated p70S6K (T389)) in which the 389th threonine (T389) was phosphorylated was measured for p70S6 kinase (p70S6K) in gastrocnemius muscle.

(Measurement of protein synthesis in gastrocnemius muscle)
The amount of protein synthesis in the gastrocnemius muscle was measured using the surface sensing of translation (SUNSET) method (Nat Methods. 2009 Apr; 6 (4): 275-7). The mouse gastrocnemius muscle was homogenized with ice-cooled Protease Inhibitor Cocktail and Tissue protein extraction reagent containing EDTA, and then centrifuged at 10,000 rpm, 10 min, 4 ° C., and the supernatant was collected. The supernatant was subjected to protein concentration quantification using Pierce BCA protein assay kit and subjected to SDS for Western blotting. The obtained sample was adjusted to a protein concentration of 10 μg / 10 μL, 10 μL was applied to Extra PAGE One Precast Gel, and electrophoresis was performed using an electrophoresis apparatus (Atto Corporation). After completion of electrophoresis, transfer was performed on a PVDF membrane using a blotting apparatus. After confirming that there was no difference in the amount of protein transferred by staining with the Ponceau S solution, Anti-puromycin (1: 3000) and Anti-β-actin (1: 2000) were added in the presence of Blocking one, and 4 Incubation was performed at 0 ° C. for 18 hours. Anti-rabbit IgG and HRP-linked Antibody (1: 10000) were added at room temperature, and after incubation for 2 hours, ECL Western Blotting Detection Reagents were added, and detection and analysis of bands were performed using FUSIONSOLO. The results were expressed as relative values with the fasting group (Fast.) As 100.

(Measurement of phosphorylated p70S6K (T389) amount in gastrocnemius muscle)
The amount of phosphorylated p70S6K (T389) in gastrocnemius muscle was measured using ELISA Kit according to the attached protocol. As the amount of phosphorylated p70S6K (T389), the amount of phosphorylated p70S6K (T389) per protein concentration in the sample was determined. The results were expressed as relative values with the fasting group (Fast.) As 100.

(Statistical analysis)
The obtained numerical value was shown by the average value +/- standard error. As a statistical test for confirming the effectiveness of the crude fraction of soyasapogenol, a multiple comparison test with the fasting group was performed using Dunnett's test after analysis of variance with one-way ANOVA. Significance level P <0.05 was considered significant. All of these analyzes were performed using Excel statistics (BellCurve).

(result)
FIG. 4 is a graph showing the amount of protein synthesis in the gastrocnemius muscle of mice administered with the crude fraction of soyasapogenol (*: P <0.05, compared with fasting group). FIG. 5 is a graph showing the amount of phosphorylated p70S6K (T389) in the gastrocnemius muscle of mice administered with the crude fraction of soyasapogenol (*: P <0.05, comparison with fasting group). The data in the graphs shown in FIGS. 4 and 5 are expressed as mean ± standard error (n = 6 or 12).
From the comparison between the satiety group (Cont.) And the fasting group (Fast.) In FIG. 4, it can be seen that the amount of protein synthesis is reduced by fasting. Compared with the fasted group, a significant increase in the amount of myoprotein synthesis was confirmed in the fasted + soyasapogenol crude fraction group (Fast. + SS) (FIG. 4).
In addition, the amount of phosphorylated p70S6K (T389) was also significantly increased in the fasted + soyasapogenol crude fraction group (Fast. + SS) compared to the fasted group (Fast.) (FIG. 5). Phosphorylation of p70S6K is important for increasing muscle weight. It was considered that the amount of muscle protein synthesis increased due to an increase in the amount of phosphorylated p70S6K (T389).

<Example 3>
Assessment of muscle protein synthesis (4 triterpenoid compounds)
Four triterpenoids of soya sapogenol A, soya sapogenol B, maslinic acid or oleanolic acid were ingested to examine the effect on protein synthesis. Soyasapogenol A, Soyasapogenol B, maslinic acid, and oleanolic acid were purchased from Sigma-Aldrich.

(Test method)
The same animals (male 7-week-old C57BL6J mice) as in Example 2 were bred and acclimatized in the same manner as in Example 2. After the acclimatization period, 54 mice were divided into the following 6 groups (9 mice in each group).
Fasting group (Cont.), Fasting group (Fast.), Fasting + Soyasapogenol group A (Fast. + SSA), Fasting + Soyasapogenol group B (Fast. + SSB), Fasting + maslinic acid group (Fast. + MA), Fasting + Oleanol Acid group (Fast. + OA)
Fasting for 24 hours was performed on 5 groups excluding the satiety group. After the fasting, immediately after the fasting, 7 hours after the fasting, and 22 hours after the fasting, divided into three times, 0.5% CMC-Na aqueous solution for the fasting group and fasting group, 0 for the fasting + triterpenoid group 26 mg / kg (26 mg / kg body weight per time) of a triterpenoid (Soyasapogenol A, Soyasapogenol B, maslinic acid or oleanolic acid) suspended in a 5% CMC-Na aqueous solution was orally administered. Twenty-three hours after fasting, 1.25 mM puromycin aqueous solution was intraperitoneally administered at 200 μL / head to all groups. Individuals whose solution leaked from the abdominal cavity when puromycin was administered, or individuals whose intraperitoneal hemorrhage was confirmed during laparotomy under anesthesia were considered to have an effect on the uptake of puromycin into the tissue, and were excluded from the analysis at this stage did. After the test was completed 24 hours after fasting, gastrocnemius muscle was collected and stored frozen at -80 ° C. For the collected gastrocnemius muscle, the amount of protein synthesis was measured by the same method as in Example 2.

(Statistical analysis)
The obtained numerical value was shown by the average value +/- standard error. When comparing the effects of the four triterpenoids, a multiple comparison test was performed using Tukey's test after analysis of variance with one-way ANOVA. Significance level P <0.05 was considered significant. All of these analyzes were performed using Excel statistics (BellCurve).

(result)
FIG. 6 is a graph showing the amount of protein synthesis in the gastrocnemius muscle of mice administered with soyasapogenol A, soyasapogenol B, maslinic acid or oleanolic acid (*: P <0.05, comparison with each group). The data of the graph shown in FIG. 6 is expressed as mean ± standard error (n = 9).
Compared with the fasting group (Fast.), A significant increase in the amount of muscle protein synthesis was confirmed in the fasting + Soyasapogenol A group (Fast. + SSA) and the fasting + Soyasapogenol B group (Fast. + SSB). Regarding the comparison between the four triterpenoids, a significant increase in the amount of muscle protein synthesis was confirmed in the fasting + soyasapogenol A group compared to the fasting + oleanolic acid group (Fast. + OA). In the fasting + soyasapogenol A group, an increasing tendency of the amount of muscle protein synthesis was confirmed as compared with the fasting + maslinic acid group (Fast. + MA). In the fasting + soyasapogenol group B, a significant increase in the amount of muscle protein synthesis was confirmed compared to the fasting + maslinic acid group and the fasting + oleanolic acid group (FIG. 6).

<Example 4>
Using normal human skeletal myoblasts (HSMM) (LONZA), the myotube differentiation promoting effect of the test substance was examined.
The soyasapogenol crude fraction produced in Preparation Example 1 was used as the test substance. In the presence of a test substance (4 μg / mL), myotube differentiation induction of HSMM was performed for 2 days at n = 3. The obtained cells were subjected to myotube staining with MHC staining and nuclear staining with Hoechst 33342 staining to quantify myotube differentiation rate.

(Preparation of test sample)
The crude soyasapogenol fraction was dissolved in dimethyl sulfoxide (DMSO). This was sequentially diluted 5-fold with a differentiation medium containing 0.1% DMSO and used for the test. As a control (Vehicle control), a differentiation medium containing 0.1% DMSO was used. As the differentiation medium, DMEM: F-12 medium (Lonza) supplemented with 2% HORSE SERUM (Thermo Fisher Scientific) was used. As a positive control, a differentiation medium containing 0.1% DMSO supplemented with 0.5 μM LDN-193189 (Sigma-Aldrich) was used.

(Growth Factor Reduced (GFR) Matrigel Matrix coat)
When inducing myotube differentiation, a 96-well plate was coated with GFR Matrigel Matrix (Corning). Thaw GFR FR Matrigel Matrix overnight at 4 ° C, dilute 100-fold with DMEM: F-12 medium (4 ° C), dispense 0.1 mL into each well of a 96-well plate on ice, and add 1 mL at room temperature. Incubated for hours. The solution was aspirated and rinsed with DMEM: F-12 medium (0.1 mL) and used for cell seeding.

(Cell pre-culture)
HSMM is a DMEM (high glucose) supplemented with a growth medium (20% FBS (fetal bovine serum) (Thermo Fisher Scientific), 4% ultraser G (PALL), 1% Antibiotic-Anticolytic Mixed Solution (Nacalai Tesque). ) (Sigma-Aldrich)). When 70% confluent, cells were detached using Trypsin-EDTA (0.05%) and phenol red (both Thermo Fisher Scientific), and 5,000 cells / 0.1 mL using growth medium / Well was seeded on a 96-well plate of GFR Matrigel Matrix and cultured in a CO ₂ incubator.

(Test substance treatment (induction of myotube differentiation))
On the next day after seeding HSMM into a GFR Matrigel Matrix-coated 96-well plate, the medium was replaced with differentiation medium (0.1 mL) supplemented with soyasapogenol crude fraction and cultured in a CO ₂ incubator for 2 days. As a control, a vehicle control (differentiation medium containing 0.1% DMSO) was used instead of the differentiation medium supplemented with the soyasapogenol crude fraction.

(Immunostaining)
After the culture, the medium was removed, 0.1 mL of 4% paraformaldehyde (PFA) (4 ° C.) was added, and the cells were fixed by incubation at 4 ° C. for 15 minutes. Next, the well was washed three times with 0.1 mL of Dulbecco's Phosphate-Buffered Saline (DPBS) (Thermo Fisher Scientific), and then a blocking / membrane permeation solution (3% BSA (bovine serum albumin) / 0.1 mL of 0.3% Triton-X 100 / DPBS) was added and incubated at room temperature for 30 minutes. Next, the primary antibody solution (prepared by adding 1/150 amount of primary antibody to 3% BSA / DPBS) was changed to 0.05 mL and incubated overnight at 4 ° C. After washing 3 times with 0.1 mL of 3% BSA / DPBS solution, secondary antibody solution (prepared by adding 1/500 volume of secondary antibody and 1/1000 volume of Hoechst 33342 to 3% BSA / DPBS) The volume was changed to 05 mL and incubated at room temperature for 2 hours. After washing with 0.1 mL of DPBS three times, 0.1 mL of DPBS was added, and image capturing and quantitative analysis were performed with Operatta CLS (registered trademark) (Perkin Elmer). The primary antibody is Anti-Myosin-Heavy Chain Purified (anti-MHC antibody) (Affymetrix), and the secondary antibody is Goast anti-Mouse IgG2b Secondary Antibody, Alexa Fluor Fisher 550, respectively. used.

(Imaging analysis)
Using the Operatta CLS®, the central 9 fields of each well were photographed using a 10 × objective lens. After acquiring images, detect nuclei and MHC positive nuclei and count them, then calculate fusion index (% of MHC positive nuclei = 100 × MHC positive nuclei / total nuclei) and quantify myotube differentiation rate did.

(Statistical analysis)
A significant difference test between the comparison test groups (control vs. soyasapogenol crude fraction addition group) was performed by Student's t-test. A two-sided test was performed, and P <0.05 was considered significant.

(result)
FIG. 7 is a graph showing the results of examining the myotube differentiation promoting effect of soyasapogenol crude fraction using normal human skeletal muscle myoblasts (*: P <0.05, comparison with control). The soyasapogenol of FIG. 7 is a soyasapogenol crude fraction addition group. In the soyasapogenol crude fraction addition group, the fusion index (% of MHC positive nuclei) was larger and the myotube differentiation rate was higher than the control. The soyasapogenol crude fraction promoted the differentiation of normal human skeletal myoblasts into myotubes.

Claims

A composition for suppressing muscle mass decrease, for suppressing muscle strength decrease, for increasing muscle mass or for increasing muscle strength, comprising at least one of soyasapogenols and / or soyasaponins as an active ingredient.
The composition according to claim 1, comprising at least one soyasapogenol as an active ingredient.
The composition according to claim 1 or 2, wherein at least one of the soyasapogenols is soyasapogenol A and / or soyasapogenol B.
The composition according to claim 1, comprising at least one soyasaponins as an active ingredient.
The composition according to claim 1 or 4, wherein at least one of the soyasaponins is at least one of group A soyasaponins and / or group B soyasaponins.
`` Muscle loss suppression '', `` Muscle maintenance '', `` Muscle increase '', `` Muscle improvement '', `` Muscle strength decrease suppression '', `` Muscle strength maintenance '', `` Muscle strength increase '', `` Muscle strength improvement '', `` Support muscle building power '' 1 or 2 of "Improvement of walking function", "Maintenance of walking function", "Improvement of motor function", "Maintenance of motor function", "Maintenance of muscle weakened by aging" and "Maintenance of muscle strength weakened by aging" The composition according to any one of claims 1 to 5, which is given the above indication.
A method for suppressing muscle mass decrease, suppressing muscle weakness, increasing muscle mass or increasing muscle strength, comprising administering one or more of soyasapogenols and / or soyasaponins.
Use of one or more soyasapogenols and / or soyasaponins for inhibiting muscle mass loss, inhibiting muscle weakness, increasing muscle mass or increasing muscle strength.